Christina Harrington Ph.D. is a Senior Staff Scientist and directs the Affymetrix Microarray Core (AMC). An Affiliate Associate Scientist at the OHSU Vaccine and Gene Therapy Institute, she also holds a faculty appointment in the Department of Molecular and Medical Genetics and a joint appointment in the Department of Physiology and Pharmacology. After receiving her B.S. in Biology from California Institute of Technology, Dr. Harrington earned her Ph.D. in Molecular, Cellular and Developmental Biology from the University of Colorado at Boulder in 1982. Upon completion of her Ph.D., Dr. Harrington worked as a Research Associate in the Neuroscience Program at Tufts University Medical School, followed by three years as a Staff Scientist at Cambridge Neuroscience, Inc., in Cambridge, MA. In 1990 she moved to England where she worked as a Staff Scientist at the National Institute for Medical Research and then as a Principal Research Fellow at the Wellcome Laboratory for Molecular Pharmacology at University College, London, focusing on the molecular regulation of neurotransmitter systems. From 1997 through 2000, she was a Senior Staff Scientist and Manager of the Scientific Liaison Group at Affymetrix, Inc., and was involved in the development of the GeneChip array expression profiling application. While at Affymetrix, Dr. Harrington directed the Affymetrix Academic User Center, a program of research collaborations with academic investigators. She is an expert in DNA microarrays, DNA and RNA processing, and gene expression. Under her direction, the OHSU Affymetrix Microarray Core provides researchers with: expression profiling and genotyping services using high-density oligonucleotide arrays; advice and training on the use of microarrays and analysis of microarray data; and support in producing and identifying high quality RNA and DNA samples for microarray analysis. In addition to her management of the AMC, she directs a research program focused on the optimization of microarray applications for biomedical research, with an emphasis on technology development for profiling of the blood transcriptome.